Keryx Biopharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Keryx Biopharmaceuticals generated cash of -$93,489,000, which is less than the previous year. Cash used in financing activities reached the amount of $76,462,000 last year. Net change in cash is therefore -$18,284,000.
Cash Flow
| 2010 | -16.20M | 19.04M | 9.18M |
|---|---|---|---|
| 2011 | -22.82M | -4.16M | 33.83M |
| 2012 | -24.76M | 4.18M | 0 |
| 2013 | -34.31M | -346K | 75.68M |
| 2014 | -81.00M | -12.99M | 112.58M |
| 2015 | -127.45M | 8.73M | 244.73M |
| 2016 | -86.60M | -2.07M | 198K |
| 2017 | -93.48M | -1.25M | 76.46M |
KERX Cash Flow Statement (2010 – 2017)
| 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 111.81M | 200.29M | 74.28M | 55.69M | 14.67M | 35.25M | 28.41M | 16.38M |
Operating activities | ||||||||
Net income | -163.44M | -161.09M | -123.14M | -111.51M | -46.73M | -25.36M | -28.36M | -20.45M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 937K | 1.00M | 596K | 306K | 54K | 35K | 47K | 60K |
Stock-based compensation expense | 18.27M | 13.98M | 16.5M | 26.95M | 5.95M | 2.16M | 2.09M | 2.47M |
| Deferred income tax benefit | 18.27M | 13.98M | 16.5M | 26.95M | 5.95M | 2.16M | 2.09M | 2.47M |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -2.91M | -1.58M | -2.82M | -834K | 0 | 0 | 0 | 0 |
Inventories | -19.49M | -2.3M | -29.18M | -7.77M | 0 | 0 | 0 | 0 |
Accounts payable | 16.02M | -490K | -7.16M | 10.66M | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -93.48M | -86.60M | -127.45M | -81.00M | -34.31M | -24.76M | -22.82M | -16.20M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | -49.77M | -24.40M | -11.26M | -9.94M | -18.36M |
Investments In Property Plant And Equipment | -1.25M | -2.07M | -2.77M | -1.48M | -346K | -24K | -57K | -23K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -1.25M | -2.07M | 8.73M | -12.99M | -346K | 4.18M | -4.16M | 19.04M |
Financing activities | ||||||||
Common Stock Issued | 75.72M | 0 | 118.28M | 115.05M | 74.75M | 0 | 30.73M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -302K | 0 | -15K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 125M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 76.46M | 198K | 244.73M | 112.58M | 75.68M | 0 | 33.83M | 9.18M |
Net Change In Cash | -18.28M | -88.48M | 126.00M | 18.58M | 41.01M | -20.57M | 6.84M | 12.02M |
Cash at end of period | 93.52M | 111.81M | 200.29M | 74.28M | 55.69M | 14.67M | 35.25M | 28.41M |
| Data source | Data source |